Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SXTC
Upturn stock ratingUpturn stock rating

China SXT Pharmaceuticals Inc (SXTC)

Upturn stock ratingUpturn stock rating
$1.58
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -23.39%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 199.57M USD
Price to earnings Ratio 0.01
1Y Target Price -
Price to earnings Ratio 0.01
1Y Target Price -
Volume (30-day avg) -
Beta 1.1
52 Weeks Range 0.95 - 11.92
Updated Date 06/29/2025
52 Weeks Range 0.95 - 11.92
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 124.5

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 318.69%
Operating Margin (TTM) -76.95%

Management Effectiveness

Return on Assets (TTM) 18.15%
Return on Equity (TTM) 57.63%

Valuation

Trailing PE 0.01
Forward PE -
Enterprise Value 190144853
Price to Sales(TTM) 109.75
Enterprise Value 190144853
Price to Sales(TTM) 109.75
Enterprise Value to Revenue 104.57
Enterprise Value to EBITDA 29.92
Shares Outstanding 116028000
Shares Floating 488309
Shares Outstanding 116028000
Shares Floating 488309
Percent Insiders 0.02
Percent Institutions 0.01

ai summary icon Upturn AI SWOT

China SXT Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

China SXT Pharmaceuticals Inc. was founded with a focus on traditional Chinese medicine (TCM) products. It has grown through product development and market expansion within China.

business area logo Core Business Areas

  • TCM Granules: Development, production, and sale of TCM granules, used for individualized prescriptions by doctors.
  • TCM Products: Manufacture and distribution of over-the-counter TCM products for various health conditions.

leadership logo Leadership and Structure

Information regarding China SXT Pharmaceutical Inc's leadership team and organizational structure is not readily available in detail within publicly accessible financial information sources.

Top Products and Market Share

overview logo Key Offerings

  • TCM Granules: Individualized TCM granule prescriptions. Market share data is unavailable. Competitors include other TCM manufacturers and pharmacies offering TCM services within China.
  • Over-the-Counter TCM Products: Various TCM products for common ailments. Market share data is unavailable. Competitors include large pharmaceutical companies and smaller TCM manufacturers in China.

Market Dynamics

industry overview logo Industry Overview

The TCM industry in China is large and growing, driven by government support and increasing consumer demand. There is considerable competition.

Positioning

China SXT Pharmaceuticals Inc is positioned as a TCM product and granule manufacturer, competing with numerous other TCM companies. Its competitive advantage, if any, is not clear from readily available information.

Total Addressable Market (TAM)

The TAM for TCM in China is significant, estimated to be in the billions of dollars annually. China SXT Pharmaceuticals Inc.'s position within the TAM is dependent on its market share which is not available publicly.

Upturn SWOT Analysis

Strengths

  • Established presence in the Chinese TCM market
  • Focus on TCM granules
  • Potential for growth in the expanding TCM market

Weaknesses

  • Limited market share data available
  • Lack of detailed financial information
  • High competition in the TCM market

Opportunities

  • Expand product offerings
  • Increase market share within China
  • Explore international markets

Threats

  • Regulatory changes in the Chinese pharmaceutical industry
  • Competition from larger pharmaceutical companies
  • Fluctuations in raw material costs

Competitors and Market Share

competitor logo Key Competitors

  • CRBP
  • JAZZ
  • VRX

Competitive Landscape

Compared to competitors, China SXT Pharmaceuticals Inc. may have a specialized focus on TCM granules, but lacks the scale and diversification of larger pharmaceutical companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trends are difficult to assess without readily available financial data following delisting.

Future Projections: Future growth projections are unavailable without analyst estimates. Which are hard to come by since it is a smaller company and recently delisted

Recent Initiatives: Recent strategic initiatives are not readily available from public sources.

Summary

China SXT Pharmaceuticals Inc. operates in the growing TCM market in China and has a targeted approach with its TCM granules. The lack of publicly available financial data makes it difficult to assess its current financial strength and future prospects accurately. Competition within the TCM market is intense, requiring China SXT to differentiate itself. Understanding the regulatory environment and adapting to market dynamics is vital for the company's success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Financial News Outlets
  • Industry Reports
  • Company Press Releases

Disclaimers:

The analysis is based on publicly available information and may not be completely accurate or up-to-date. Market share and financial data are estimates and should be treated with caution.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About China SXT Pharmaceuticals Inc

Exchange NASDAQ
Headquaters -
IPO Launch date 2019-01-04
Chairman of the Board & Co-CEO Mr. Feng Zhou
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 75
Full time employees 75

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.